Get started
BeyondSpring, Inc.BB

BeyondSpring, Inc.

1.44USDR
−0.06−4.00%
At close at Mar 28, 20:00 GMT
USD
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals Options

BYSI fundamentals

Key facts

Market capitalization‪58.06 M‬USD
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−0.40USD
Founded2010
Employees (FY)40
CEOLan Huang
Websitebeyondspringpharma.com
About

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in Florham Park, NJ.

Ownership
‪‪40.30 M‬‬
Free Float shares
‪‪29.29 M‬‬ (72.69%)
Closely held shares
‪‪11.01 M‬‬ (27.31%)
Free Float shares
‪‪29.29 M‬‬ (72.69%)
Closely held shares
‪‪11.01 M‬‬ (27.31%)
Capital structure
Market cap
‪‪58.06 M‬‬
Debt
‪‪589.00 K‬‬
Minority interest
‪‪3.91 M‬‬
Cash & equivalents
‪‪2.92 M‬‬
Enterprise value
‪‪74.34 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪58.06 M‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
31.24x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
31.24x
Valuation ratios
H1 '23
H2 '23
H1 '24
‪0.00‬
‪13.00‬
‪26.00‬
‪39.00‬
‪52.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−1,500.0%‬
‪−1,300.0%‬
‪−1,100.0%‬
‪−900.0%‬
‪−700.0%‬
H1 '23
H2 '23
H1 '24
‪‪−13.50 M‬‬
‪‪−9.00 M‬‬
‪‪−4.50 M‬‬
‪0.00‬
‪‪4.50 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−9.00 M‬‬
‪‪−6.00 M‬‬
‪‪−3.00 M‬‬
‪0.00‬
‪‪3.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−9.00 M‬‬
‪‪−6.00 M‬‬
‪‪−3.00 M‬‬
‪0.00‬
‪‪3.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Targeted Protein Degradation Platform
By country
Period: 2024
United States

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
2020
2021
2022
2023
2025
‪0.00‬
‪‪40.00 M‬‬
‪‪80.00 M‬‬
‪‪120.00 M‬‬
‪‪160.00 M‬‬
Actual
Estimate
Earnings
Next:May 6, 2026
2020
2021
2022
2023
2025
‪−2.20‬
‪−1.10‬
‪0.00‬
‪1.10‬
‪2.20‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

BYSI does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
H1 '23
H2 '23
H1 '24
‪0.00‬
‪‪6.00 M‬‬
‪‪12.00 M‬‬
‪‪18.00 M‬‬
‪‪24.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪10.00 M‬‬
‪‪20.00 M‬‬
‪‪30.00 M‬‬
‪‪40.00 M‬‬
Assets
Liabilities